Opinion

Video

Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

Video content above is prompted by the following:

  • Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Related Videos
1 KOL is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
5 experts are featured in this series.
1 KOL is featured in this series.
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo